Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Title Type $ Amount Activity Investigatorsort descending Unit Sponsor Date
Examining Global Gene Expression in Skin Biopsies from People with Hypermobile EDS Grant $69,020.00 Research Christina Laukaitis Medicine Ehlers-Danlos Society 03/2020
A Multicenter, Double-Blind, RanDomized, Placebo-Controlled, Parallel-Group Study to determine the EffIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects with Fabry Disease Contract $85,957.00 Clinical Trial Christina Laukaitis Medicine Idorsia Pharmaceutical (Switzerland) 11/2020
Health Assessment - Consultative Examinations (CE) Contract $252,806.00 Other Sponsored Activity Christina Vasquez Arthritis Center-Research Arizona Department of Economic Security 01/2021
Establishing Strategies to Ameliorate Amyloid Pathology in Light Chain Amyloidosis Grant $329,045.00 Research Christopher Glembotski COM Phx Campus Administration Scripps Research Institute 09/2021
New Translational Research Platform Using Gene Sequencing and Stem Cells To Diagnose and Treat Atrial Fibrillation (AF) Grant $167,051.45 Research Christopher Glembotski COM Phx Campus Administration University of Arizona Foundation 01/2022
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy Grant $2,459,972.00 Research Christopher Glembotski COM Phx Campus Administration National Heart, Lung, and Blood Institute 01/2022
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy Grant $1,237,307.00 Research Christopher Glembotski COM Phx Campus Administration National Heart, Lung, and Blood Institute 01/2021
ATF6 is Required for ANP Secretion from the Heart Grant $729,125.00 Research Christopher Glembotski COM Phx Campus Administration National Heart, Lung, and Blood Institute 12/2020
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia Grant $349,932.00 Research Christopher Glembotski COM Phx Campus Administration National Heart, Lung, and Blood Institute 12/2020
IPA for Chase Irwin Contract $64,549.00 Research Christopher Glembotski COM Phx Campus Administration United States Department of Veterans Affairs 03/2022
FLowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH) Contract $125,613.76 Clinical Trial Christopher Goettl COM Phx Radiology Inari Medical 02/2020
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease Grant $3,770,471.00 Research Christopher Hulme Pharmacology and Toxicology National Institute on Aging 04/2020
University of Michigan O'Brien Kidney Translation Core Center Grant $39,125.00 Research Chyi Chyi Chong Medicine University of Michigan 03/2021
VA Medical Educational Costs Ancillary Contract - Residency Programs $61,636.00 Instruction Conrad Clemens COM Academic Affairs United States Department of Veterans Affairs 06/2021
Defining the role of PIM kinases in hypoxia-induced prostate cancer invasion Fellowship $92,072.00 Research Training Corbin Jensen Cellular & Molecular Medicine National Cancer Institute 02/2022
A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Through 5 Years of Age Contract $421,673.20 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Vertex Pharmaceuticals, Incorporated 08/2021
Standardizing Treatment of Pulmonary Exacerbations in Pediatrics (STOP-PEDS) Pilot Funding Request (STUDY) Contract $60,516.00 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Indiana University 05/2021
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal F Contract $587,778.40 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Vertex Pharmaceuticals, Incorporated 03/2022
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous f Contract $577,503.72 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Vertex Pharmaceuticals, Incorporated 03/2022
Training Long Term - Pediatric Pulmonary Centers Grant $1,700,000.00 Instruction Cori Daines Pediatrics Health Resources and Services Administration 05/2020
A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older Contract $484,469.00 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Vertex Pharmaceuticals, Incorporated 02/2022
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... Contract $273,767.50 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Janssen Research & Development, LLC 01/2020
A Phase 1/2a Randomized, Double-blind, Two-part, Dose-ascending, Multicenter Study of the Safety and Pharmacokinetics of Ar-501 (Gallium Citrate), Administered via Inhalation, in Healthy Adult and P. Contract $408,060.92 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Aridis Pharmaceuticals Inc. 10/2021
A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People with Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY) Contract $34,865.00 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Seattle Children's Hospital 11/2020
CF Learning Network: Implementation Phase Grant $48,496.00 Research Cori Daines Pediatrics Cincinnati Children's Hospital Medical Center 04/2020

Pages